The FDA has authorized what it describes as the first COVID-19 diagnostic test that detects whether a person has the specific antibodies known to block the coronavirus from entering and infecting human cells.
These neutralizing antibodies are seen as a strong biomarker of potential immunity against the disease—compared to other antibodies created by the body, which have only been used as evidence of previous exposure to the virus.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,